

# Galunisertib

## Selective TGF- $\beta$ receptor I kinase inhibitor

Galunisertib is a potent, selective, and orally bioavailable inhibitor of transforming growth factor-beta receptor type I (TGF- $\beta$ RI) kinase. It blocks TGF- $\beta$ -induced signaling by inhibiting Smad2 phosphorylation, a key step in the TGF- $\beta$ /Smad pathway. Galunisertib exhibits an  $IC_{50}$  of 56 nM in cell-free assays.

Key features and applications include:

- **Selective TGF- $\beta$ RI Inhibition:** Specifically targets ALK5 (TGF- $\beta$ RI), minimizing off-target effects on other kinases.
- **Smad2 Pathway Blockade:** Inhibits TGF- $\beta$ -induced Smad2 phosphorylation, reducing transcription of pro-fibrotic and pro-tumorigenic genes.
- **Cancer Stem Cell Modulation:** Shown to inhibit self-renewal and survival of cancer stem-like cells.
- **Orally Active:** Suitable for *in vivo* studies and clinical development.

Research Applications:

- Tumor microenvironment and immune evasion studies
- Fibrosis and epithelial-to-mesenchymal transition (EMT) models
- Cancer stem cell biology
- Combination therapy with immune checkpoint inhibitors or chemotherapy

Relevant disease states include:

- **Cancer:** Investigated in clinical trials for hepatocellular carcinoma, glioblastoma, pancreatic, and colorectal cancers due to its ability to suppress tumor growth and metastasis.
- **Fibrotic Diseases:** Explored in models of liver, lung, and kidney fibrosis where TGF- $\beta$  signaling drives pathological tissue remodeling.



- **Immuno-Oncology:** Enhances anti-tumor immunity by reducing TGF- $\beta$ -mediated immunosuppression in the tumor microenvironment.

Ordering Information


Order Online »

ENZ-CHM376-0025	25mg
-----------------	------

Manuals, SDS & CofA

View Online »







## Handling & Storage

Use/Stability	As indicated on product label or CoA when stored as recommended.
Short Term Storage	-20°C
Long Term Storage	-20°C
Shipping	Ambient Temperature

## Regulatory Status

RUO - Research Use Only

## Product Details

Alternative Name	LY2157299, 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
Appearance	White solid.
CAS	700874-72-2
Couple Target	TGF-beta receptor
Couple Type	Inhibitor
Formula	$C_{22}H_{19}N_5O$
Identity	Determined by NMR.
MW	369.43
Purity	≥98%
Solubility	Soluble in DMSO (up to 25 mg/mL)

Last modified: July 28, 2025



ENZO LIFE SCIENCES,  
INC.  
Phone: 800.942.0430  
[info-  
usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

European Sales Office  
ENZO LIFE SCIENCES  
(ELS) AG  
Phone: +41 61 926 8989  
[info-  
eu@enzolifesciences.com](mailto:info-eu@enzolifesciences.com)

Belgium, The Netherlands  
& Luxembourg  
Phone: +32 3 466 0420  
[info-  
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

France  
Phone: +33 472 440 655  
[info-  
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

Germany  
Phone: +49 7621 5500 526  
[info-  
de@enzolifesciences.com](mailto:info-de@enzolifesciences.com)

UK & Ireland  
Phone (UK customers):  
0845 601 1488  
Phone: +44 1392 825900  
[info-  
uk@enzolifesciences.com](mailto:info-uk@enzolifesciences.com)